v3.26.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
AbbVie Stock Purchase Agreement
At-The-Market Offerings
Follow-on offering
Common Stock
Common Stock
AbbVie Stock Purchase Agreement
Common Stock
At-The-Market Offerings
Additional Paid-in Capital
Additional Paid-in Capital
AbbVie Stock Purchase Agreement
Additional Paid-in Capital
At-The-Market Offerings
Additional Paid-in Capital
Follow-on offering
Accumulated Deficit
Beginning balance at Dec. 31, 2024 $ 17,598       $ 0     $ 401,351       $ (383,753)
Beginning balance (in shares) at Dec. 31, 2024         3,268,299              
Stockholders' Deficit                        
Issuance of common stock, net of issuance costs   $ 2,810 $ 2,017           $ 2,810 $ 2,017    
Issuance of common stock, net of issuance costs (in shares)           310,559 110,747          
Vesting of restricted common stock (in shares)         7,952              
Exercise of stock options 5             5        
Exercise of stock options (in shares)         648              
Stock-based compensation expense 1,535             1,535        
Net loss (13,265)                     (13,265)
Ending balance at Mar. 31, 2025 10,700       $ 0     407,718       (397,018)
Ending balance (in shares) at Mar. 31, 2025         3,698,205              
Beginning balance at Dec. 31, 2025 35,273       $ 0     454,062       (418,789)
Beginning balance (in shares) at Dec. 31, 2025         4,530,641              
Stockholders' Deficit                        
Issuance of common stock and prefunded warrants, net of issuance costs       $ 37,256             $ 37,256  
Issuance of common stock and prefunded warrants, net of issuance costs (in shares)         535,611              
Issuance of common stock, net of issuance costs (in shares)     0                  
Issuance of common stock to settle the liabilities to issue common stock 7,333       $ 1     7,332        
Issuance of common stock to settle liabilities to issue common stock (in shares)         708,223              
Issuance of common stock in connection with the exercise of prefunded warrants (in shares)         535,611              
Vesting of restricted common stock (in shares)         7,952              
Exercise of stock options                  
Exercise of stock options (in shares) 109                      
Stock-based compensation expense $ 2,211             2,211        
Net loss (9,529)                     (9,529)
Ending balance at Mar. 31, 2026 $ 72,545       $ 1     $ 500,862       $ (428,318)
Ending balance (in shares) at Mar. 31, 2026         5,782,536